Material/Methods: ERb1 and ERb2 expression was examined immunohistochemically on paraffin-embedded thyroid tissues from 106 patients with PTC and 30 patients with NTG.
Results:
There was significant difference in the subcellular localization of ERb1 (P<0.001), but not in the positive percentage, between PTC and NTG specimens. No significant difference was found in the positive percentage or the subcellular distribution of ERb2 expression between PTC and NTG specimens. Both nuclear and nucleocytoplasmic ERb1 expressions were significantly lower in PTC lesions than in NTG tissue (P<0.001 and P<0.05, respectively), while ERb2 expression was significantly higher in the former than the latter (P<0.05). ERb1 expression in reproductive-aged (18~45 years) female patients with PTC was lower than that in age-matched male patients (P<0.05), while ERb2 expression had the opposite expression profile (P<0.05). There was no significant difference in ERb1 and ERb2 expression between reproductive-aged and advanced reproductive-aged (>45 years) female patients with PTC.
Conclusions:
This preliminary study indicates that the expression patterns of ERb1 and ERb2 differ between malignant PTC lesions and benign NTG tissue, and their expression might be involved in the female predominance of PTC during the reproductive years. The clinical and biological significance of these results await further investigation. 
Background
Thyroid cancer represents the most frequent endocrine malignancy, and its incidence has significantly increased in the past several decades [1] . Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 80% of all thyroid cancers. The incidence of thyroid cancer is 3 to 5 times more frequent in women than in men. This female predominance, which is greatest during reproductive age, is observed in all geographical areas and ethnic groups [2] . The use of oral contraceptives appears to result in a moderately increased risk of developing thyroid cancer [3] [4] [5] . An elevated risk was also reported in women who used estrogens for gynecological problems, but not for low-dose estrogen replacement therapy in postmenopausal women [3, 6] . In fact, the incidence of thyroid cancer decreases after menopause [7] . The difference in incidence between the sexes suggests that the growth and progression of thyroid tumors is influenced by female sex hormones, particularly estrogen, which has been clearly implicated in the development and progression of breast, endometrial, and prostate cancers [8] [9] [10] .
Estrogens are the predominant sex hormones in females. They exert their action in target tissues via binding to 1 of the 2 estrogen receptors (ER), ERa or ERb. Like other steroid hormone receptors, ERs act as dimers to regulate transcriptional activation. Full transcriptional activation by ERs is mediated by synergism between 2 activation domains, Activation Function-1 (AF-1) at the N terminus and AF-2 in the ligand-binding domain. Both ERa and ERb contain the potent AF-2 function, but unlike ERa, ERb seems to have a weaker corresponding AF-1 function, and thus depends more on the ligand-dependent AF-2 for its transcriptional activation function [11] . Recently, several splice variants of ERb with truncations or insertions in the C-terminal ligand-binding domain (ERb1~ERb5) have been described and widely studied in breast, endometrial, and prostate cancers [8] [9] [10] . Among the exon 8 splice variants of ERb, the expression and function of ERb2 (ERbcx) is well-documented. It appears that ERb2 lacks the AF-2 core region and does not bind to ERb ligands, but does bind to estrogen responsive elements (EREs) as a homodimer and as a heterodimer with either wild-type ERa or ERb [12, 13] . ERb2 preferentially forms a heterodimer with ERa rather than with ERb, inhibiting DNA binding by ERa. ERb2 shows a dominant negative activity on transactivation mediated only by ERa [12, 14, 15] . The possible molecular mechanism is that ERb2 induces proteasome-dependent degradation of ERa, presumably through the formation of ERb2/ERa heterodimers [16] .
ERs have been described in both neoplastic and non-neoplastic human thyroid tissues by immunohistochemical studies. In PTC, ERa expression is significantly higher in premenopausal women than in post-menopausal women and in men of various ages [17] . No consistent findings were reported about the correlation between ERb expression and clinicopathological findings including age, menopausal status, sex, and/or histological type of thyroid lesions [17, 18] . To the best of our knowledge, the expression of ERb splice variants in PTC has not yet been evaluated by immunohistochemistry in the English literature.
In this paper, we used immunohistochemical method to determine the expression of ERb1 (wild-type ERb) and the C-terminal truncated splice variant ERb2 (ERbcx) in benign and malignant thyroid tissues, and to further explore the reasons for the higher incidence of PTC in women of reproductive age.
Material and Methods

Clinical material
Thyroid specimens were obtained from 106 patients with PTC and 30 patients with NTG who were first admitted to our hospital with ≤3 years' duration and who underwent a standard thyroidectomy between 2007 and 2010. Patient records were obtained from the Medical Records Department at our hospital and also from pathology reports. Their diagnoses were confirmed by histopathological examination. None of these patients had a history of familial thyroid cancer or neck external irradiation. The patients were divided into 2 groups on the basis of age: reproductive-aged patients (18~45 years) and advanced reproductive-aged patients (>45 years). Of the 106 PTC patients, there were 50 reproductive-aged female patients (mean age, 32.50±8.71 years; age range, 18~45 years), 39 advanced reproductive-aged female patients (mean age, 56.87±7.89 years; age range, 46~81 years), and 17 reproductive-aged male patients (mean age, 32.88±7.17 years; age range, 23~45 years). NTG patients comprised 30 reproductive-aged patients (mean age, 38.43±4.90 years; age range, 24~45 years).
Immunohistochemistry
Immunohistochemical staining was performed for both ERb1 and ERb2 to evaluate immunoreactivity in the abovementioned tissue samples. Paraffin-embedded tissue sections fixed in formalin were used. Slides were deparaffinized, rehydrated, and subjected to microwave heat antigen retrieval in 10 mM citrate buffer (pH 6.0) for 20~25 min. After blocking endogenous peroxidase activity, sections were incubated with primary antibodies against ERb1 (1: 20; Clone PPG5/10, Serotec) and ERb2 (1: 400; Clone 57/3, Serotec) overnight at 4°C. After washing with PBS, staining was performed by the Elivision™ plus two-step system (Maixin Bio, China). Immunoreactivity was visualized using the chromogen 3,3'-diamino-benzidine (DAB) (Maixin Bio, China). Slides were then counterstained with hematoxylin, washed, dehydrated with alcohol and xylene, and mounted onto coverslips. Appropriate positive and negative controls were run simultaneously with the patient specimen.
Evaluation of immunohistochemistry
Immunohistochemistry staining for ERb1 and ERb2 was interpreted using the Allred score [19, 20] . Briefly, a proportion score (PS) represented the estimated proportion of tumor cells staining positive, as follows: 0 (none); 1 (1/100); 2 (1/100 to 1/10); 3 (1/10 to 1/3); 4 (1/3 to 2/3); and 5 (>2/3). An intensity score (IS) represented the average intensity of the positive cells: 0 (none); 1 (weak); 2 (intermediate); and 3(strong). The proportion and intensity scores were then added to obtain a total score (TS), which could range from 0 to 8, and "positive" is defined as scores ≥3. Two investigators (Dong WW and Huang YH) independently 
results
Expression of ERb splice variants in reproductive-aged female patients with PTC and NTG
The subcellular distribution of ERb1 and ERb2 in PTC and NTG are shown in Table 1 . Figure 1 illustrates the subcellular localization of ERb1 and ERb2 in PTC and NTG. There was significant difference in the subcellular localization of Nuclear ERb1 expression in PTC was significantly lower than that in NTG (Z=-3.213, P=0.001), and nucleocytoplasmic ERb1 expression in PTC was also lower than that in NTG (Z=-2.557, P=0.014). ERb2 expression in PTC was higher than that in NTG (Z=-2.170, P=0.030) .
Association between expression of ERb splice variants and gender and age of patients with PTC
ERb1 expression in reproductive-aged female patients with PTC was lower than that in corresponding male patients (Z=-2.387, P=0.017). On the contrary, ERb2 expression in reproductive-aged female patients with PTC was higher than that in age-matched male patients (Z=-2.141, P=0.032). There was no significant difference in ERb1 and ERb2 expression between reproductive-aged and advanced reproductive-aged female patients with PTC.
discussion
Unlike the traditional ERa, which is localized in the nuclei of cancer cells, ERb splice variants have been detected in both the nucleus and cytoplasm of cancer cells [8, 21] . However, the expression pattern of ERb splice variants in thyroid cancer has not been adequately explored. Our data show nuclear and cytoplasmic expression of ERb1 and ERb2 were found in both PTC and NTG specimens, except cytoplasmic expression of ERb2 in NTGs. Specifically, ERb1 was predominantly localized in the nucleus of NTG cells, and in both the nucleus and cytoplasm of PTC cells, whereas ERb2 was primarily localized in the nucleus of both NTG and PTC cells. It has been reported that ERb isoforms (ERb1, ERb2, ERb3, and ERb5) are detected only in the nuclei of Barrett's metaplasia cells negative for dysplasia, and a significant number of carcinomas show cytoplasmic ERb immunoreactivity, which is especially the case with ERb2 [21] . It is speculated that perhaps there is a different level of expression of ERb splice variants between normal or benign tissue and cancer tissue where certain isoforms with predominantly cytoplasmic immunoreactivity are associated with the malignant phenotype [22] . It may be ERb1 in PTCs and ERb2 in esophageal adenocarcinomas.
Consistent with findings in breast cancer, ERb2 protein levels significantly increased in ductal carcinoma in situ (DCIS) and invasive breast cancer, compared to the adjacent normal gland [23] . We also found a decrease in both nuclear and nucleocytoplasmic ERb1 expression and an increase in ERb2 expression in PTC compared to NTG, indicating a role for ERb2 in carcinogenesis that opposes the protective effect of wild-type ERb1. However, the role of ERb2 is quite the opposite in endometrioid carcinoma. Chakravarty et al reported that ERb2 expression was decreased in endometrioid carcinoma compared to proliferative endometrium, and was decreased in higher grade tumors [24] ; indicating that the roles of ERb splice variants are specific to cancer types. Currently, it is widely believed that ERb has limited importance in thyroid cancer since no significant difference has been found in its expression between males and females, in benign versus malignant lesions, or in premenopausal versus postmenopausal females [18] . However, these data may reflect the fact that the presence of ERb splice variants was not taken into consideration. In prostate cancer, no significant correlation was found between ERb1 or ERb2 expression and age [25] . In primary colorectal cancer, no association between sex and ERb1 and ERb2 protein expression was found [26] . However, a positive correlation between age and ERb1 expression was identified in invasive breast cancer [27] . In our study we found that ERb1 and ERb2 expression was associated with sex but not with age, which may partly explain the female predominance of PTC during the reproductive years. Thus, the associations between ERb splice variants with sex and age warrant further investigation.
In our study we determined the localization and expression pattern of ERb splice variants and its significance in PTC. However, we did not study the relationship between ERb splice variants and ERa, as all ERb splice variants inhibit ERa transcriptional activity. We plan to study the association between ERb splice variants and ERa in PTC in future studies.
conclusions
This study investigated the expression pattern of ERb splice variants in various types of thyroid lesions at the protein level using specific well-validated antibodies. Furthermore, it highlights the importance of ERb splice variants in the development of PTC. The female predominance of PTC during the reproductive years may be associated with the expression of ERb splice variants; thus, their clinical and biological significance merit further investigation.
